Company / R&D per Share
MADRIGAL PHARMACEUTICALS, INC. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$17.66
FY2025
5-year range
$11.91 / $17.66
FY2021-FY2025
Trend
+48.2%
vs FY2024
Sector context
#6 of 208
Health Care
What the data says
Among 208 Health Care companies, MADRIGAL PHARMACEUTICALS, INC. is in the top 3% for r&d per share. R&D per Share has fluctuated over the past 10 years, ranging from $1.72 in FY2018 to $17.66 in FY2025.
Based on SEC 10-K filings.
17.66 in FY2025 with a 5-year CAGR of +8.1%. Top quartile in the Health Care sector.
Improved from $15.04 to $17.66 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +7.2%
- 5-Year CAGR
- +8.1%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 208This company $17.66 Sector average $28.82
▼
-38.7% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 48.2% year-over-year.
- Ranks #6 out of 208 companies in the Health Care sector.
- Lowest r&d per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $17.66 | +48.2% |
| FY2024 | $11.91 | -20.8% |
| FY2023 | $15.04 | +5.0% |
| FY2022 | $14.32 | +8.3% |
| FY2021 | $13.23 | +10.4% |
| FY2020 | $11.98 | +155.0% |
| FY2019 | $4.70 | +173.8% |
| FY2018 | $1.72 | -13.9% |
| FY2017 | $1.99 | -34.9% |
| FY2016 | $3.06 | +282.6% |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026